Keenova Therapeutics plc - Company Profile
Powered by 
All the sales intelligence you need on Keenova Therapeutics plc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Keenova Therapeutics plc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Keenova Therapeutics plc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on Keenova Therapeutics plc’s latest deals, number of deals and deal values, alongside insights into its key mergers and acquisitions.
Number of Deals
Deal Value ($M)
Latest Deals
| Announced Date | Headline | Deal Type | Acquirers/Investors/Surviving Entity | Issuer/Partner/Target |
|---|---|---|---|---|
| 14 Sep 2022 | Mallinckrodt Enters Manufacturing Agreement with Patheon for Terlivaz | Contract Service Agreement |
Mallinckrodt LLC
|
Patheon NV
|
| 19 May 2021 | Mandos Acquires Adrabetadex from Vtesse | Asset Transaction |
Mandos LLC
|
Vtesse Inc (Inactive)
|
| 16 Jul 2020 | Mallinckrodt Exercises License Option from Silence Therapeutics | Licensing Agreement |
Mallinckrodt Plc
|
Silence Therapeutics Plc |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
Contact the team or request a demo to find out how our data can drive your business forward
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer